U.S. Markets closed

Oramed Pharmaceuticals Inc. (ORMP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.16+0.01 (+0.12%)
At close: 4:00PM EDT
People also watch
OHRPVBLTCNATCANFONTX
Interactive chart
Previous Close8.15
Open8.16
Bid6.44 x 100
Ask10.00 x 400
Day's Range8.12 - 8.36
52 Week Range5.70 - 9.04
Volume23,915
Avg. Volume37,095
Market Cap108.48M
Beta1.06
PE Ratio (TTM)-8.56
EPS (TTM)-0.95
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Trade prices are not sourced from all markets
  • Oramed to Present at Conferences Next Week
    PR Newswire11 days ago

    Oramed to Present at Conferences Next Week

    JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, ...

  • Oramed Granted Canadian Patent for GLP-1 Analog Capsule
    PR Newswire20 days ago

    Oramed Granted Canadian Patent for GLP-1 Analog Capsule

    JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, "Methods and Compositions for Oral Administration of Exenatide". Oramed's oral GLP-1 capsule based on the Company's Protein Oral Delivery (PODTM) technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.

  • Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017
    Capital Cube24 days ago

    Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Oramed Pharmaceuticals, Inc. reports financial results for the quarter ended February 28, 2017. We analyze the earnings along side the following peers of Oramed Pharmaceuticals, Inc. – Novo Nordisk A/S Sponsored ADR Class B, Ultragenyx Pharmaceutical, Inc. and Lexicon Pharmaceuticals, Inc. (NVO-US, RARE-US and LXRX-US) that have also reported for this ... Read more (Read more...)